These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18621926)

  • 1. Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity.
    Bumpus NN; Hollenberg PF
    Mol Pharmacol; 2008 Oct; 74(4):990-9. PubMed ID: 18621926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites.
    Kent UM; Mills DE; Rajnarayanan RV; Alworth WL; Hollenberg PF
    J Pharmacol Exp Ther; 2002 Feb; 300(2):549-58. PubMed ID: 11805216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
    Zhang H; Sridar C; Kenaan C; Amunugama H; Ballou DP; Hollenberg PF
    J Pharmacol Exp Ther; 2011 Sep; 338(3):803-9. PubMed ID: 21659470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of serine 360 by a reactive intermediate of 17-alpha-ethynylestradiol results in mechanism-based inactivation of cytochrome P450s 2B1 and 2B6.
    Kent UM; Sridar C; Spahlinger G; Hollenberg PF
    Chem Res Toxicol; 2008 Oct; 21(10):1956-63. PubMed ID: 18729327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of a single residue (K262R) in P450 2B6 leads to loss of mechanism-based inactivation by phencyclidine.
    Shebley M; Hollenberg PF
    Drug Metab Dispos; 2007 Aug; 35(8):1365-71. PubMed ID: 17460030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.
    Kent UM; Lin HL; Mills DE; Regal KA; Hollenberg PF
    Chem Res Toxicol; 2006 Feb; 19(2):279-87. PubMed ID: 16485904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation.
    Bumpus NN; Sridar C; Kent UM; Hollenberg PF
    Drug Metab Dispos; 2005 Jun; 33(6):795-802. PubMed ID: 15769884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms.
    Bumpus NN; Kent UM; Hollenberg PF
    J Pharmacol Exp Ther; 2006 Jul; 318(1):345-51. PubMed ID: 16611850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.
    Xu C; Ogburn ET; Guo Y; Desta Z
    Drug Metab Dispos; 2012 Apr; 40(4):717-25. PubMed ID: 22232427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.
    Talakad JC; Kumar S; Halpert JR
    Drug Metab Dispos; 2009 Mar; 37(3):644-50. PubMed ID: 19074527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of the threonine 407, aspartic acid 417, and threonine 419 residues in P450 2B1 in metabolism.
    Sridar C; Harleton E; Hollenberg PF
    Biochem Biophys Res Commun; 2005 Dec; 338(1):386-93. PubMed ID: 16157292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism-based inactivation of cytochromes P450 2B1 and P450 2B6 by 2-phenyl-2-(1-piperidinyl)propane.
    Chun J; Kent UM; Moss RM; Sayre LM; Hollenberg PF
    Drug Metab Dispos; 2000 Aug; 28(8):905-11. PubMed ID: 10901699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of substrate metabolism by cytochromes P450 2B1, 2B4, and 2B6: relationship of heme spin state, catalysis, and the effects of cytochrome b5.
    Reed JR; Hollenberg PF
    J Inorg Biochem; 2003 Jan; 93(3-4):152-60. PubMed ID: 12576277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling.
    Shebley M; Kent UM; Ballou DP; Hollenberg PF
    Drug Metab Dispos; 2009 Apr; 37(4):745-52. PubMed ID: 19144770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms.
    Harleton E; Webster M; Bumpus NN; Kent UM; Rae JM; Hollenberg PF
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1011-9. PubMed ID: 15121764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver.
    Hanna IH; Reed JR; Guengerich FP; Hollenberg PF
    Arch Biochem Biophys; 2000 Apr; 376(1):206-16. PubMed ID: 10729207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of inactivation of human cytochrome P450 2B6 by phencyclidine.
    Jushchyshyn MI; Wahlstrom JL; Hollenberg PF; Wienkers LC
    Drug Metab Dispos; 2006 Sep; 34(9):1523-9. PubMed ID: 16782764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.
    Ward BA; Gorski JC; Jones DR; Hall SD; Flockhart DA; Desta Z
    J Pharmacol Exp Ther; 2003 Jul; 306(1):287-300. PubMed ID: 12676886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine.
    Jushchyshyn MI; Kent UM; Hollenberg PF
    Drug Metab Dispos; 2003 Jan; 31(1):46-52. PubMed ID: 12485952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution.
    Gay SC; Shah MB; Talakad JC; Maekawa K; Roberts AG; Wilderman PR; Sun L; Yang JY; Huelga SC; Hong WX; Zhang Q; Stout CD; Halpert JR
    Mol Pharmacol; 2010 Apr; 77(4):529-38. PubMed ID: 20061448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.